← Leaderboards
Julia L Hurwitz
St. Jude Children'S Research Hospital
$4,606,182
Attributed
$6,088,515
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$13,132,654 · 13
By mechanism
P01$8,427,809 · 3
R01$4,234,562 · 3
P51$470,283 · 7
Top collaborators
- John P Devincenzo5 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Allen Portner$2,845,159
- Toru Takimoto$5,846,505
- Karen S Slobod$1,967,097
- Jerry L Shenep$126,000
Others in their field
Top investigators on “Vaccine Development”
- Lawrence Corey · Fred Hutchinson Cancer Center$718,120,301
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$554,939,981
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$394,383,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$392,263,550
- Dennis R. Burton · Scripps Research Institute$312,611,400
Research focus
Vaccine DevelopmentVirusVaccinesResearch StudyInfectionAids VaccinesAidsBaseResearch PersonnelHiv Envelope ProteinPreventImmune ResponseVaccine EfficacyVaccinia VirusSourceHuman Immunodeficiency Virus 1Neutralizing AntibodyResponseDesignChildLifeClinical TrialsImmuneAntibodies
Grant awards (29)
Influence of maternal antibodies on a Sendai virus-vectored RSV vaccine$566,924
R01 · FY2014 · AI · contact PI
Influence of maternal antibodies on a Sendai virus-vectored RSV vaccine$586,166
R01 · FY2013 · AI · contact PI
Influence of maternal antibodies on a Sendai virus-vectored RSV vaccine$617,512
R01 · FY2012 · AI · contact PI
Influence of maternal antibodies on a Sendai virus-vectored RSV vaccine$617,720
R01 · FY2011 · AI · contact PI
Influence of maternal antibodies on a Sendai virus-vectored RSV vaccine$576,345
R01 · FY2010 · AI · contact PI
HIV-envelope-specific CD4+ T-cell activation and functional potentials$411,350
R01 · FY2010 · AI · contact PI
HIV VACCINE RATIONALE$84,079
P51 · FY2010 · RR · contact PI
HIV-envelope-specific CD4+ T-cell activation and functional potentials$420,000
R01 · FY2009 · AI · contact PI
HIV VACCINE RATIONALE$58,149
P51 · FY2009 · RR · contact PI
Immune Response and Vaccine Efficacy in a Rodent Model$252,662
P01 · FY2008 · AI · contact PI
HIV VACCINE RATIONALE$63,253
P51 · FY2008 · RR · contact PI
Immune Response and Vaccine Efficacy in a Rodent Model$218,420
P01 · FY2007 · AI · contact PI
HIV VACCINE RATIONALE$71,638
P51 · FY2007 · RR · contact PI
Immune Response and Vaccine Efficacy in a Rodent Model$236,937
P01 · FY2006 · AI · contact PI
Immune Response and Vaccine Efficacy in a Rodent Model$234,002
P01 · FY2005 · AI
DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE$998,405
P01 · FY2004 · AI
Immune Response and Vaccine Efficacy in a Rodent Model$233,789
P01 · FY2004 · AI
EVALUATION OF A MULTI-ENVELOPE HIV VACCINE$47,161
P51 · FY2004 · RR
DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE$1,191,222
P01 · FY2003 · AI
EVALUATION OF A MULTI-ENVELOPE HIV VACCINE$61,544
P51 · FY2003 · RR
DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE$1,253,959
P01 · FY2002 · AI
MULTI-TIER AIDS VACCINE--MANUFACTURE AND TESTING$0
P01 · FY2002 · AI
DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE$2,517,641
P01 · FY2001 · AI
MARROW TRANSPLANT IN CANCER THERAPY T CELL RECOVERY$222,514
R01 · FY2001 · CA
MULTI-TIER AIDS VACCINE--MANUFACTURE AND TESTING$0
P01 · FY2001 · AI
DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE$1,082,912
P01 · FY2000 · AI
MARROW TRANSPLANT IN CANCER THERAPY T CELL RECOVERY$216,031
R01 · FY2000 · CA
MULTI-TIER AIDS VACCINE--MANUFACTURE AND TESTING$207,860
P01 · FY2000 · AI
MULTI ENVELOPE HIV VACCINE SAFETY$84,459
P51 · FY2000 · RR